Holding Big Pharma Accountable Through Pharmaceutical Class Actions
Patients place extraordinary trust in pharmaceutical companies. A prescription medication can control a chronic illness, prevent a life-threatening reaction, or help someone recover from a serious medical condition. Patients generally have no practical way to inspect the manufacturing process, verify the accuracy of a drug company’s safety representations, or determine whether competitors have been unlawfully prevented from offering a more affordable alternative.
When a medication is contaminated, its risks are concealed, or its price is inflated through deceptive or anticompetitive conduct, the harm can extend nationwide. One patient might face an unexplained medical concern while another pays hundreds of dollars more for the same prescription. A health plan, pharmacy, or family may see only its own financial loss. A class action can bring those experiences together and expose the corporate decisions behind them.
Working with an experienced California product liability class action attorney can help consumers determine whether a medication issue reflects a broader manufacturing defect, a misleading practice, or an unlawful pharmaceutical pricing scheme.
A Single Pharmaceutical Practice Can Affect an Entire Market
Prescription drugs typically move through a complex system involving manufacturers, ingredient suppliers, distributors, pharmacies, insurers, pharmacy benefit managers, physicians, and patients. Misconduct at one point in that system can affect thousands or even millions of purchases.
A contaminated ingredient can be used across numerous medication lots before the problem is discovered. A misleading marketing campaign can influence prescribing decisions across the country. An agreement that delays generic competition can keep prices artificially high for years. The financial loss or medical risk facing one consumer may appear too limited or difficult to pursue alone, even when the company earned substantial revenue from the same conduct repeated throughout the market.
Class actions allow consumers, healthcare plans, and other purchasers with common claims to seek relief collectively. The size of the class can also create enough financial exposure to challenge practices that would remain profitable if each person were left to pursue a separate claim.
Contaminated Blood Pressure Drugs Placed Manufacturing Safety Under Scrutiny
The recalls involving valsartan, losartan, and irbesartan demonstrate how pharmaceutical litigation can address a safety problem embedded in the manufacturing process. These medications belong to a group of drugs commonly prescribed to treat high blood pressure and certain heart conditions.
In July 2018, the U.S. Food and Drug Administration announced recalls of certain valsartan products after testing identified N-nitrosodimethylamine, commonly known as NDMA. The FDA described NDMA as a probable human carcinogen and reported that some recalled products contained amounts above acceptable exposure levels. Additional recalls later involved other angiotensin II receptor blocker medications and several nitrosamine impurities.
The resulting multidistrict litigation included personal injury claims as well as certified classes pursuing economic-loss and medical-monitoring relief. Consumers alleged that they paid for medications they would not have purchased had they known the drugs contained the impurities at issue. Medical-monitoring claims focused on the costs associated with evaluating health risks allegedly created by exposure.
In July 2026, the court granted final approval to three economic-loss class settlements involving certain valsartan, irbesartan, and losartan products. The settling defendants denied wrongdoing and disputed the allegations concerning the impurities and their potential effects. The broader litigation included additional claims beyond those resolved by the settlements.
The litigation shows how class actions can address a dangerous-drug problem even when every consumer has not developed the same physical injury. Recovering the purchase price of contaminated medication and seeking uniform medical-monitoring relief can present common questions that are distinct from an individual claim for cancer or another diagnosed condition.
EpiPen Litigation Challenged Practices Affecting Access to Emergency Medication
An EpiPen delivers epinephrine during a severe allergic reaction. For patients at risk of anaphylaxis, immediate access to the medication can be a matter of life or death. Litigation surrounding EpiPen pricing alleged that pharmaceutical companies used anticompetitive and deceptive practices that caused consumers and third-party payors to pay inflated prices.
Class plaintiffs reached a $345 million settlement with Pfizer-related defendants and a separate $264 million settlement with Mylan-related defendants. The combined settlements totaled $609 million. The defendants did not admit wrongdoing, and the court’s approval of the settlements did not decide the disputed allegations against them.
The importance of the litigation extended beyond the size of the settlement funds. High prices for emergency medication can force families to make difficult decisions about how many devices they can afford, where they will keep them, and how frequently they can replace expired injectors. Litigation concerning a life-saving drug can bring public attention to the relationship between pharmaceutical pricing practices and a patient’s ability to maintain reliable access to treatment.
The case also illustrates why consumer and third-party payor classes can be important in pharmaceutical litigation. An individual purchaser may not possess the data required to evaluate rebate arrangements, formulary exclusions, market share, or communications among companies. Class discovery can uncover evidence capable of showing whether the higher price was the result of ordinary market forces or a coordinated practice affecting purchasers throughout the country.
Lidoderm Litigation Targeted Delayed Generic Competition
Generic medications generally provide patients and health plans with lower-cost alternatives to brand-name drugs. Pharmaceutical companies can lawfully resolve patent disputes, but an agreement becomes subject to antitrust scrutiny when it is alleged to compensate a generic manufacturer for delaying competition.
The Lidoderm litigation arose from allegations that pharmaceutical companies entered into an unlawful pay-for-delay arrangement involving a lidocaine patch used to treat pain associated with post-herpetic neuralgia. Purchasers claimed that the arrangement delayed lower-priced generic competition and required them to pay more for both brand-name and generic versions of the medication.
In 2018, a federal court granted final approval to a $104.75 million settlement for end payors. Separate settlements for direct purchasers brought the total recovery associated with the litigation to more than $270 million. The end-payor class included individuals, employee benefit plans, unions, and other entities that paid or reimbursed the cost of Lidoderm.
The Federal Trade Commission has identified pay-for-delay agreements as a significant pharmaceutical competition concern because delaying generic entry can keep drug costs higher for consumers and taxpayers. The agency has estimated that anticompetitive pharmaceutical patent settlements cost consumers and taxpayers billions of dollars in additional drug expenses each year.
A pharmaceutical antitrust class action can return a portion of those overpayments to purchasers while placing pressure on drug companies to compete on lawful terms. Greater generic competition can also improve public health by making prescribed treatment financially accessible to more patients.
Suboxone Litigation Examined an Alleged Market-Switching Strategy
Suboxone is used in the treatment of opioid use disorder. Antitrust plaintiffs alleged that the manufacturer shifted the market from Suboxone tablets to a film version as generic competition for the tablets approached. The claims asserted that the company used the switch and related conduct to preserve its market position and interfere with lower-cost competition.
A federal court granted final approval to a $385 million settlement for a certified class of direct purchasers in February 2024. A separate $30 million settlement was established for an end-payor class that included consumers and other purchasers. The settlements resolved disputed allegations without a finding that the defendant had committed the alleged wrongdoing. (Hagens Berman)
The public-health consequences of pharmaceutical competition can be especially significant when the medication treats addiction or another condition requiring continuing care. Delayed generic entry can increase costs for patients, treatment programs, insurers, and public agencies. Higher prices can narrow treatment options in communities already struggling to meet demand.
Suboxone litigation demonstrates how a class action can challenge a business strategy that might appear technical when viewed through patent filings, product formulations, and regulatory submissions. For the people who rely on the medication, the alleged conduct can translate into higher prescription costs and fewer affordable paths to treatment.
Pharmaceutical Class Actions Can Produce Broader Safety Benefits
Financial compensation is an important part of pharmaceutical class litigation, but it is not the only measure of its value. Litigation can require drug companies to produce internal testing records, safety reports, marketing plans, pricing data, regulatory communications, and documents concerning manufacturing decisions.
Evidence developed through discovery can reveal when a company first learned of a possible problem, how it responded to consumer complaints, and whether it accurately communicated material information to regulators, physicians, and patients. Public filings can also alert consumers and healthcare professionals to risks that were previously difficult to identify.
Class settlements can reimburse prescription costs, fund medical monitoring, address overpayments, or require changes to business conduct. The pressure created by litigation can strengthen quality-control systems, improve risk disclosures, discourage misleading marketing, and protect access to generic medication. Those effects can benefit patients who never receive a settlement payment because they reduce the likelihood that the challenged conduct will continue unchecked.
Physical Injury Claims May Follow a Different Legal Path
The term “class action” is sometimes used broadly to describe any large group of pharmaceutical lawsuits. Dangerous-drug litigation does not always proceed as a class action.
A claim seeking compensation for a physical injury commonly requires evidence concerning the patient’s medical history, dosage, length of use, other medications, underlying conditions, diagnosis, and prognosis. Those individualized questions can make a single class-wide personal injury trial impractical. Injured patients may instead pursue individual lawsuits coordinated through multidistrict litigation, where cases share pretrial proceedings but retain their separate identities.
Claims based on a uniform economic loss, common misrepresentation, contaminated product, delayed generic entry, or shared need for medical monitoring can be more suitable for class treatment. Under Rule 23 of the Federal Rules of Civil Procedure, a proposed federal class must satisfy requirements involving numerosity, commonality, typicality, and adequate representation. A damages class must also establish that common questions predominate and that class treatment is superior to other available methods of resolving the dispute.
The distinction protects class members by ensuring that claims are grouped only when a collective case can fairly resolve the issues they share.
Consumer and Antitrust Laws Support Pharmaceutical Accountability
Pharmaceutical class actions can rely on several legal theories, depending on the conduct involved. Claims challenging agreements that suppress generic competition may arise under Sections 1 and 2 of the Sherman Antitrust Act, which address unlawful restraints of trade and monopolization. California purchasers may also have claims under the state’s Cartwright Act.
Deceptive representations, concealed information, and unfair business practices can support claims under California’s Unfair Competition Law, Business and Professions Code § 17200, or the Consumers Legal Remedies Act. Product liability, warranty, fraud, and state consumer protection laws can provide additional remedies when medications are contaminated, defective, or sold through misleading representations.
The available claims depend on what the company did, what information consumers received, the type of loss involved, and whether the same conduct affected a definable group of purchasers or patients.
Contact The Kalfayan Law Firm
If you purchased a contaminated medication, paid an inflated price for a prescription drug, or learned that a pharmaceutical company may have concealed information affecting your health, your experience could be part of a wider practice. Prescription records, pharmacy receipts, medication packaging, insurance statements, safety notices, and communications from the manufacturer can help establish what product you received and how the conduct affected you.
The Kalfayan Law Firm, APC represents consumers in complex product liability, consumer protection, and antitrust litigation in California and nationwide. Contact an experienced consumer class action lawyer at The Kalfayan Law Firm for a free consultation about a pharmaceutical practice that may have caused widespread financial loss or placed consumers at risk.
